Table 1.
Criteria for Autoimmune Disease7 | NMO | MS |
---|---|---|
Immune response to a precise autoantigen in all patients | aquaporin 422, 23 | Multiple antigens have been described, not present in all patients12, 13, 17, 18, 19, 20 |
Lesion reproducibility after administration of autoantibody or T cells | Exacerbation of EAE model after adoptive transfer of neuromyelitis optica Abs27 | |
Animal: induction of lesion by antigen immunization | EAE model: induced by myelin oligodendrocyte glycoprotein, proteolipid protein, myelin basic protein28 and reactivated CD4+ T cells29 | |
Autoantibody or T cell isolation form lesion or serum | aquaporin 4 antibodies27, 30 | |
Autoantibody titers or T-cell levels associated with disease activity | Higher antibody titers during relapse than during remission31 | |
Autoimmune disorders or autoantigens associated with the disease | Sjogren syndrome, SLE32 | No association in population-based cohort studies33 |
Immune absorption with purified autoantigen abrogates pathogenic autoantibody or T cell | ||
Reduction of autoantibody or T cell associated with clinical improvement | Plasma exchange34 | Plasma exchange35, 36 |
Abbreviations: EAE, experimental autoimmune encephalomyelitis; MBP, myelin basic protein; PLP, proteolipid protein.
Adapted from Paul WE, Schwartz RS, Datta SK. Autoimmunity and autoimmune diseases. In Fundamental immunology. New York: Raven Press; 1989. p. 819-66; and Rodriguez M, Warrington AE, Pease LR. Invited article: human natural autoantibodies in the treatment of neurologic disease. Neurology 2009;72(14):1269–76.